Two new studies have shown promising data supporting the use of eculizumab or satralizumab to significantly reduce the risk for neuromyelitis optica spectrum disorder relapses, which can leave patients either blind or paralyzed.
Genentech recently presented data from its SAkuraSky phase 3 multicenter, randomized, double-masked, placebo-controlled study evaluating the efficacy and safety of satralizumab added to baseline immunosuppressant therapy in patients with neuromyelitis optica spectrum disorder (NMOSD).
In addition, researchers from the Mayo Clinic published the findings of the Prevention
Uncategorized